Stephen Davis
CEO at ACADIA Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: ACADIA Pharmaceuticals Inc., 3 years.
ACADIA Pharmaceuticals Inc.
Director · CEO
Chief executive roles
Until September 2024
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −31,747 | $15.28 | $485,094 |
| Aug 16, 2024 | ACADIA Pharmaceuticals Inc. | Grant or award | +17,333 | — | — |
| Aug 16, 2024 | ACADIA Pharmaceuticals Inc. | Grant or award | +44,782 | — | — |
| May 2, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −11,427 | $16.94 | $193,573 |
| May 1, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +22,391 | — | — |
| Apr 8, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −8,858 | $17.87 | $158,292 |
| Apr 8, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −17,716 | $17.87 | $316,585 |
| Apr 5, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +17,333 | — | — |
| Apr 5, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +34,666 | — | — |
| Mar 27, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −17,714 | $17.90 | $317,081 |
| Mar 25, 2024 | ACADIA Pharmaceuticals Inc. | Grant or award | +34,666 | — | — |
| Feb 26, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −5,577 | $24.67 | $137,585 |
| Feb 23, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +10,946 | — | — |
| Jan 8, 2024 | ACADIA Pharmaceuticals Inc. | Open-market sale | −3,732 | $29.96 | $111,811 |
| Jan 6, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +9,528 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.